The Effectivity of Pfizer vaccine on oral immunological biomarkers sIgA and Interleukin-21

The Effectivity of Pfizer vaccine on oral immunological biomarkers sIgA and Interleukin-21

Background: The most widely used vaccination against SARS-associated coronavirus (SARS-CoV-2) is the Pfizer vaccine, which provides protection against this virus. However, its ability to safeguard the oral cavity is unclear, and neither are the exact immunological biomarker levels it activates. This...

Full description

Bibliographic Details
Main Authors:	Dhuha Ali, Ghada Taha
Format:	Article
Language:	English
Published:	Zagazig University, Faculty of Medicine 2024-02-01
Series:	Microbes and Infectious Diseases
Subjects:	sars-cov-2 vaccination pfizer ((bnt162b2) il-21 siga
Online Access:	https://mid.journals.ekb.eg/article_333196_4f012df6f08cd05881e8aaccac2fac02.pdf

Similar Items

Effect of Covid-19 vaccine on some immunological salivary biomarkers (sIgA and Interleukine-17)
by: Dhuha Ali, et al.
Published: (2023-07-01)

Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic review
by: Ahmad R. Al‐Qudimat, et al.
Published: (2022-07-01)

Immune Response in Regard to Hypersensitivity Reactions after COVID-19 Vaccination
by: Ming-Hsiu Hsieh, et al.
Published: (2022-07-01)

Clinical characteristics and respiratory care in hospitalized vaccinated SARS-CoV-2 patients
by: Jose Rafael Teran-Tinedo, et al.
Published: (2022-06-01)

Antibody responses to BNT162b2 SARS‐CoV‐2 mRNA vaccine among healthcare workers and residents of long‐term care facilities: A cohort study in Northern Italy
by: Costanza Vicentini, et al.
Published: (2023-02-01)

Acute myocarditis following administration of BNT162b2 vaccine
by: Mhd Baraa Habib, et al.
Published: (2021-01-01)

Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)
by: Maria Antonietta Isgrò, et al.
Published: (2022-07-01)

A racing heart post‐Pfizer/BioNTech BNT162b2
by: Hooi Khee Teo, et al.
Published: (2022-10-01)

The relation between salivary sIgA level and caries incidence in Down syndrome children
by: Rosdiana Rosdiana, et al.
Published: (2012-06-01)

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
by: Nick K Jones, et al.
Published: (2021-04-01)

BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
by: Shir Azrielant, et al.
Published: (2024-02-01)

Unilateral Pleural Effusion after Third Dose of BNT162b2 mRNA Vaccination: Case Report
by: Nikolaos K. Athanasiou, et al.
Published: (2023-02-01)

COVID-19 vaccination-related attendance at a pediatric emergency department in Singapore among 12- to 18-year old adolescents
by: Nicholas Beng Hui Ng, et al.
Published: (2022-11-01)

Acute pancreatitis in pregnancy following COVID-19 vaccine: a case report
by: Rajib Kumar Dey, et al.
Published: (2022-09-01)

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
by: Mohammad Altermanini, et al.
Published: (2023-08-01)

The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies
by: Violet Ankunda, et al.
Published: (2024-02-01)

Shared and Non-Shared sIgA-Coated and -Uncoated Bacteria in Intestine of Mother–Infant Pairs
by: Mengfan Ding, et al.
Published: (2022-08-01)

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
by: Farah M. Shurrab, et al.
Published: (2022-01-01)

Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile
by: Diego A. Díaz-Dinamarca, et al.
Published: (2023-08-01)

Why COVID vaccines for young children (5–11 years) are not essential at this moment in time?
by: Hamid A. Merchant
Published: (2022-12-01)

Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern
by: Jia Ming Low, et al.
Published: (2022-01-01)

Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines
by: Cynthia M. Rohde, et al.
Published: (2023-02-01)

Clinical and Laboratory Features in the Israeli Population with COVID-19 Infection after Pfizer-BioNTech mRNA Booster Vaccination
by: Ariel Israel, et al.
Published: (2022-04-01)

Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
by: Eun-Ju Kim, et al.
Published: (2023-06-01)

Optic neuritis secondary to the Pfizer-BioNTech-162b2 COVID-19 vaccine managed with plasmapheresis: A case report and review
by: Paras P Shah, et al.
Published: (2022-01-01)

Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines
by: Roberta Mancuso, et al.
Published: (2022-10-01)

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01)

Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine
by: Jun Nomura, et al.
Published: (2023-01-01)

Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study
by: Morales-Núñez JJ, et al.
Published: (2022-08-01)

Protection against MIS-C outweighs the risk of myocarditis after Covid-19 vaccination in children
by: Marcello Mariani, et al.
Published: (2022-08-01)

DYNAMICS OF SIgA CONTENT IN BREAST MILK WHEN RISK FACTORS AND LACTATIONAL CHARACTERISTICS ARE CONSIDERED
by: Nataliya Gromnatska
Published: (2022-06-01)

BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy
by: Bernadetta Płatkowska-Adamska, et al.
Published: (2022-11-01)

Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review
by: Karen Cortés-Sarabia, et al.
Published: (2022-06-01)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
by: Hiroaki Akiyama, et al.
Published: (2021-01-01)

Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
by: Khalid Hajissa, et al.
Published: (2021-08-01)

The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster
by: Wolszczak Biedrzycka B, et al.
Published: (2022-12-01)

Tozinameran (Pfizer, BioNTech) and Elasomeran (Moderna) Efficacy in COVID-19—A Systematic Review of Randomised Controlled Trial Studies
by: Piotr Ratajczak, et al.
Published: (2023-05-01)

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
by: Hao Zhou, et al.
Published: (2021-08-01)

Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands
by: Lotus Leonie van den Hoogen, et al.
Published: (2022-09-01)

Concomitant Peripheral and Pulmonary Arterial Thromboembolism 35 Days After SARS-CoV-2 mRNA Vaccine
by: Ahmet Can Topçu, et al.
Published: (2023-04-01)